ANTI-MERS-COV NUCLEOPROTEIN. CLONE 46 (C15-1886-690)

General description

Spike glycoprotein (UniProt: P0DTC2; also known as S glycoprotein, E2, Peplomer protein) is encoded by the S (also known as 2) gene (Gene ID: 43740568) in Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The SARS-CoV-2 is a positive-strand RNA virus that causes severe respiratory syndrome in human. The mature SARS-CoV-2 contains 4 structural proteins: Envelope (E), Membrane (M), Nucleocapsid (N), and the Spike protein (S). E and M proteins help in viral assembly and N protein is needed for RNA synthesis. The S protein is a single-pass type I, homotrimeric, membrane glycoprotein that is responsible for virus binding and entry into host cell. It is synthesized with a signal peptide (aa 1-12), which is subsequently cleaved off to generate the mature protein that contains an extracellular domain (aa 13-1213), a transmembrane domain (aa 1214-1234), and a cytoplasmic domain 1235-1273). The S protein is further processed into S1 (aa 13-685) and S2 (aa 686-1273) subunits by host cell furin. The presence of a furin polybasic cleavage site in S protein from SARS-CoV-2 sets it apart from S protein in SARS-CoV that possesses a monobasic S1/S2 cleavage site. The S1 subunit has the receptor binding domain (RBD; aa 319-541) that mediates entry of SARS-CoV-2 into sensitive cells through the peptidase domain of host Angiotensin-converting enzyme 2 (ACE2) with high affinity (KD = 15 nM). The S2 domain (aa 686-1213), which is reported to be well conserved, is responsible for membrane fusion.

Specificity

Clone 1A4-3F8 is a mouse monoclonal antibody that specifically detects receptor binding domain (RBD) of SARS-CoV-2 Spike protein. It targets an epitope within the C-terminal region of RBD.

Immunogen

His-tagged recombinant fragment from the C-terminal region of the receptor binding domain (RBD) of SARS-CoV-2 Spike protein.

Application

Quality Control Testing

Evaluated by Western Blotting in lysate from HEK293T cells expressing full-length SARS-CoV-2 spike protein.

Western Blotting Analysis (WB): A 1:250 dilution of this antibody detected SARS-CoV-2 spike glycoprotein in lysate from HEK293T cells expressing full-length SARS-CoV-2 spike protein.

Tested Applications

Immunoprecipitation Analysis: 2 μg from a representative lot immunoprecipitated SARS-CoV-2 spike glycoprotein in HEK293T S-P2A-GFP (Data courtesy of Dr. Stefan Schüchner, Dr. Egon Ogris, Max Perutz Labs, Medical University of Vienna, Austria).

Western Blotting Analysis: 0.1 μg from a representative lot detected SARS-CoV-2 spike glycoprotein in lysates from HEK293T cells expressing full-length spike protein of SARS-CoV-2 (Data courtesy of Dr. Stefan Schüchner, Dr. Egon Ogris, Max Perutz Labs, Medical University of Vienna, Austria).

Immunofluorescence Analysis: A representative lot detected SARS-CoV-2 spike glycoprotein in HEK293T cells expressing full-length spike protein of SARS-CoV-2 (Data courtesy of Dr. Stefan Schüchner, Dr. Egon Ogris, Max Perutz Labs, Medical University of Vienna, Austria).

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user

Anti-SARS-CoV-2 Spike RBD, clone 1A4-3F8, Cat. No. MABF3085, is a mouse monoclonal antibody that detects the receptor binding domain of SARS-CoV-2 spike protein and is tested for use in Immunofluorescence, Immunoprecipitation, and Western Blotting.

Physical form

Purified mouse monoclonal antibody IgG1 in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

Storage and Stability

Recommended storage: +2°C to +8°C.

Other Notes

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.